Roche Aktie - 0QQ6

Professionelle Tools für Privatanleger.

Premium

Current Price

229,20

Gebot

0,00

Fragen

0,00

Volumen

6.365

0,00 Tagesbereich 0,00

229,20 52-Wochen-Bereich 229,20

Marktkapitalisierung

Handelsende

229,20

Handelsbeginn

Letzte Trade

285.4

(O)

Letzter Handelszeitpunkt

Finanzvolumen

VWAP

Durchschnittliches Volumen (3 Mio.)

4.076

Ausgegebene Aktien

0,00

Dividendenrendite

Kurs-Gewinn-Verhältnis

0,00

Gewinn pro Aktie (EPS)

Erlöse

58,72B

Nettogewinn

11,5B

Sektor

Pharmaceutical Preparations

Branche

Pharmaceutical Preparations

Website

www.roche.com

Hauptsitz

Basel, Che

Gegründet

Roche Holding Ag is listed in the Pharmaceutical Preparations sector of the Londoner Börse with ticker 0QQ6. The last closing price for Roche was CHF229,20. Over the last year, Roche shares have traded in a share price range of CHF 229,20 to CHF 229,20.

Roche currently has 0 shares in issue.

Roche purchases shares in tender offer for Poseida Therapeutics, Inc.

Roche purchases shares in tender offer for Poseida Therapeutics, Inc. Basel, 8 January 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Roche’s wholly owned subsidiary Blue Giant...

Roche’s Phase IIb study of prasinezumab missed primary endpoint, but suggests possible benefit in early-stage Parkinson’s disease

Roche’s Phase IIb study of prasinezumab missed primary endpoint, but suggests possible benefit in early-stage Parkinson’s disease PADOVA study showed numerical delay in motor progression and...

Roche transforms mass spectrometry diagnostics with launch of cobas® Mass Spec solution

Roche transforms mass spectrometry diagnostics with launch of cobas® Mass Spec solution Roche launches its cobas® Mass Spec solution, bringing mass spectrometry to the routine clinical labClinical...

Roche’s Vabysmo prefilled syringe (PFS) approved in the EU for three retinal conditions that can cause blindness

Roche’s Vabysmo prefilled syringe (PFS) approved in the EU for three retinal conditions that can cause blindness Vabysmo PFS is the first and only prefilled syringe containing a bispecific...

Roche receives CE Mark for new and updated molecular cobas 6800/8800 systems, enhancing laboratory efficiency and testing capabilities

Roche receives CE Mark for new and updated molecular cobas 6800/8800 systems, enhancing laboratory efficiency and testing capabilities The new cobas 6800/8800 systems 2.0 enhances throughput, run...

New and updated data for Roche's fixed-duration Columvi and Lunsumio at ASH 2024 reinforce their potential to improve outcomes for people with lymphoma

New and updated data for Roche's fixed-duration Columvi and Lunsumio at ASH 2024 reinforce their potential to improve outcomes for people with lymphoma Long-term data confirm fixed-duration...

Roche commences tender offer for all shares of Poseida Therapeutics, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right for up to $4.00 per share in cash

Roche commences tender offer for all shares of Poseida Therapeutics, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right for up to $4.00 per share in cash Basel, 9...

Five-year results confirm Roche’s Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma

Five-year results confirm Roche’s Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma Exploratory long-term follow-up analysis of the phase III POLARIX...

FDA accepts supplemental Biologics License Application for Roche’s Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma

FDA accepts supplemental Biologics License Application for Roche’s Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma Application is based on data from the...

Roche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies

Roche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies Acquisition supports Roche’s Pharma Strategy and...

Zeitraum †	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	229.2	229.2	229.2	3868	229.2	DE
4	229.2	229.2	229.2	3129	229.2	DE
12	229.2	229.2	229.2	4076	229.2	DE
26	229.2	229.2	229.2	4534	229.2	DE
52	229.2	229.2	229.2	4951	229.2	DE
156	229.2	229.2	229.2	6058	229.2	DE
260	229.2	229.2	229.2	4950	229.2	DE

0QQ6 - Frequently Asked Questions (FAQ)

What is the current Roche share price?

The current share price of Roche is CHF 229,20

What is the 1 year trading range for Roche share price?

Roche has traded in the range of CHF 229,20 to CHF 229,20 during the past year

What is the reporting currency for Roche?

Roche reports financial results in CHF

What is the latest annual turnover for Roche?

The latest annual turnover of Roche is CHF 58,72B

What is the latest annual profit for Roche?

The latest annual profit of Roche is CHF 11,5B

What is the registered address of Roche?

The registered address for Roche is GRENZACHERSTRASSE 124, BASEL, 4070

What is the Roche website address?

The website address for Roche is www.roche.com

Which industry sector does Roche operate in?

Roche operates in the PHARMACEUTICAL PREPARATIONS sector

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
WSLWorldsec Ld	2,00p (60,00%)	105,37k
BLUBlue Star Capital Plc	12,00p (45,45%)	1,54M
NTQEnteq Technologies Plc	1,40p (40,00%)	19,81M
BANKFiinu Plc	10,25p (36,67%)	12,95M
TIRTiger Royalties And Investments Plc	0,16p (28,00%)	139,07M
PODPPod Point Group Holdings Plc	10,88p (-35,20%)	6,83M
PALMPanther Metals Plc	53,50p (-35,15%)	226,06k
NOGNostrum Oil & Gas Plc	2,51p (-23,82%)	117,6k
ADMEAdm Energy Plc	0,175p (-22,22%)	1,19M
PRDPredator Oil & Gas Holdings Plc	5,85p (-20,95%)	5,72M
NTVONativo Resources Plc	0,0021p (10,53%)	844,9M
TRPTower Resources Plc	0,0305p (-1,61%)	507,22M
PREMPremier African Minerals Limited	0,027p (-3,57%)	504,81M
SYMESupply@me Capital Plc	0,003p (-13,04%)	461,39M
ORCPOracle Power Plc	0,016p (-5,88%)	308,68M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Roche Holding Ag (0QQ6)

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

Über Roche Holding Ag

0QQ6 Neueste Nachrichten

Roche purchases shares in tender offer for Poseida Therapeutics, Inc.

Roche’s Phase IIb study of prasinezumab missed primary endpoint, but suggests possible benefit in early-stage Parkinson’s disease

Roche transforms mass spectrometry diagnostics with launch of cobas® Mass Spec solution

Roche’s Vabysmo prefilled syringe (PFS) approved in the EU for three retinal conditions that can cause blindness

Roche receives CE Mark for new and updated molecular cobas 6800/8800 systems, enhancing laboratory efficiency and testing capabilities

New and updated data for Roche's fixed-duration Columvi and Lunsumio at ASH 2024 reinforce their potential to improve outcomes for people with lymphoma

Roche commences tender offer for all shares of Poseida Therapeutics, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right for up to $4.00 per share in cash

Five-year results confirm Roche’s Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma

FDA accepts supplemental Biologics License Application for Roche’s Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma

Roche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies

Roche purchases shares in tender offer for Poseida Therapeutics, Inc.

Roche’s Phase IIb study of prasinezumab missed primary endpoint, but suggests possible benefit in early-stage Parkinson’s disease

Roche transforms mass spectrometry diagnostics with launch of cobas® Mass Spec solution

Roche’s Vabysmo prefilled syringe (PFS) approved in the EU for three retinal conditions that can cause blindness

Roche receives CE Mark for new and updated molecular cobas 6800/8800 systems, enhancing laboratory efficiency and testing capabilities

New and updated data for Roche's fixed-duration Columvi and Lunsumio at ASH 2024 reinforce their potential to improve outcomes for people with lymphoma

Roche commences tender offer for all shares of Poseida Therapeutics, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right for up to $4.00 per share in cash

Five-year results confirm Roche’s Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma

0QQ6 - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Roche Holding Ag (0QQ6) Börsenkurse

Roche Holding Ag (0QQ6)

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

Über Roche Holding Ag

0QQ6 Neueste Nachrichten

0QQ6 - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen